These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1914080)

  • 1. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.
    Villani F; Galimberti M; Zunino F; Monti E; Rozza A; Lanza E; Favalli L; Poggi P
    Cancer Chemother Pharmacol; 1991; 28(5):365-9. PubMed ID: 1914080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
    Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
    G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin.
    Villani F; Galimberti M; Monti E; Piccinini F; Lanza E; Rozza A; Favalli L; Poggi P; Zunino F
    Free Radic Res Commun; 1990; 11(1-3):145-51. PubMed ID: 2074045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of superoxide dismutase and catalase on the delayed toxicity of doxorubicin].
    Villani F; Galimberti M; Poggi P; Rozza A; Lanza E; Favalli L; Scavini C
    Cardiologia; 1992 Oct; 37(10):709-11. PubMed ID: 1296877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
    Villani F; Galimberti M; Monti E; Cova D; Lanza E; Rozza-Dionigi A; Favalli L; Poggi P
    Toxicol Appl Pharmacol; 1990 Feb; 102(2):292-9. PubMed ID: 2105541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.
    Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M
    Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between doxorubicin-induced ECG changes and myocardial alterations in rats.
    Villani F; Monti E; Piccinini F; Favalli L; Lanza E; Rozza Dionigi A; Poggi P
    Tumori; 1986 Jun; 72(3):323-9. PubMed ID: 3739010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.
    Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P
    Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione.
    Yoda Y; Nakazawa M; Abe T; Kawakami Z
    Cancer Res; 1986 May; 46(5):2551-6. PubMed ID: 3697994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
    Fadillioğlu E; Erdoğan H; Söğüt S; Kuku I
    J Appl Toxicol; 2003; 23(1):71-4. PubMed ID: 12518339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy.
    Rashikh A; Ahmad SJ; Pillai KK; Kohli K; Najmi AK
    Biomed Pharmacother; 2012 Mar; 66(2):138-43. PubMed ID: 22386366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Effects of Liraglutide, Oxytocin and Granulocyte Colony-Stimulating Factor in Doxorubicin-Induced Cardiomyopathy Model: An Experimental Animal Study.
    Taşkıran E; Erdoğan MA; Yiğittürk G; Erbaş O
    Cardiovasc Toxicol; 2019 Dec; 19(6):510-517. PubMed ID: 31054117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats.
    Iqbal M; Dubey K; Anwer T; Ashish A; Pillai KK
    Pharmacol Rep; 2008; 60(3):382-90. PubMed ID: 18622063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluoperazine does not affect doxorubicin cardiotoxicity in the rat.
    Villani F; Monti E; Piccinini F; Favalli L; Rozza Dionigi A; Lanza E; Poggi P
    Anticancer Res; 1988; 8(4):659-63. PubMed ID: 3178155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects.
    Jensen RA; Acton EM; Peters JH
    J Cardiovasc Pharmacol; 1984; 6(1):186-200. PubMed ID: 6199603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats.
    Villani F; Galimberti M; Monti E; Piccinini F; Poggi P; Lanza E; Rozza A; Favalli L
    Pharmacol Res; 1991 Feb; 23(2):195-202. PubMed ID: 2062794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats.
    Rashikh A; Abul Kalam Najmi ; Akhtar M; Mahmood D; Pillai KK; Ahmad SJ
    Hum Exp Toxicol; 2011 Feb; 30(2):102-9. PubMed ID: 20418268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of myofibrillar ATPase activity and isomyosin shift in delayed doxorubicin cardiotoxicity.
    Cappelli V; Moggio R; Monti E; Paracchini L; Piccinini F; Reggiani C
    J Mol Cell Cardiol; 1989 Jan; 21(1):93-101. PubMed ID: 2523975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.
    Danesi R; Bernardini N; Agen C; Costa M; Zaccaro L; Pieracci D; Malvaldi G; Del Tacca M
    Cancer Chemother Pharmacol; 1992; 29(4):261-5. PubMed ID: 1472260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes.
    O'Connell JL; Romano MM; Campos Pulici EC; Carvalho EE; de Souza FR; Tanaka DM; Maciel BC; Salgado HC; Fazan-Júnior R; Rossi MA; Simões MV
    Exp Toxicol Pathol; 2017 Apr; 69(4):213-219. PubMed ID: 28153388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.